What Is Glycopyrronium? Uses, Dosage, and What You Need to Know in 2026

Glycopyrronium is one of those medications that can show up on a prescription for a child with cerebral palsy, an adult with COPD, a person with excessive underarm sweating, or a patient in a preoperative holding area. It's the same compound doing very different jobs. This guide explains what glycopyrronium is, all of its approved uses, the different brand names, and how dosing works for each indication.

What Is Glycopyrronium?

Glycopyrronium is an anticholinergic medication — specifically, a muscarinic receptor antagonist. It works by blocking acetylcholine from binding to muscarinic receptors throughout the body, which reduces secretions, slows the gut, relaxes airway smooth muscle, and decreases sweating.

One important property: glycopyrronium is a synthetic quaternary ammonium compound. This means it does not cross the blood-brain barrier to a significant degree, which is why it causes fewer central nervous system effects (like confusion or sedation) compared to anticholinergic drugs that do cross the BBB, such as atropine or scopolamine.

You may see it called glycopyrrolate — especially on U.S. prescription labels. Glycopyrrolate is the U.S. Adopted Name (USAN), while glycopyrronium is the International Nonproprietary Name (INN) used in most of the world. They are exactly the same compound.

Brand Names of Glycopyrronium

Robinul (1 mg tablets) and Robinul Forte (2 mg tablets): Oral tablets for peptic ulcer disease and general anticholinergic indications. Available as generic.

Cuvposa (1 mg/5 mL oral solution): FDA-approved for chronic severe drooling in children ages 3–16 with neurological conditions.

Dartisla ODT: Orally disintegrating tablet formulation for adult peptic ulcer indications.

Qbrexza (2.4% topical cloth): FDA-approved June 2018 — the first drug specifically approved to treat primary axillary hyperhidrosis (excessive underarm sweating), for adults and children 9 and older.

Seebri Neohaler (15.6 mcg inhalation capsules) and Lonhala Magnair (25 mcg/mL nebulizer solution): COPD maintenance treatment — long-acting muscarinic antagonist (LAMA) inhalers.

Bevespi Aerosphere: Combination COPD inhaler (glycopyrrolate + formoterol fumarate, a LABA).

Generic injectable (0.2 mg/mL): Intravenous/intramuscular use in hospital and surgical settings.

FDA-Approved Uses of Glycopyrronium

Glycopyrronium has FDA approval for multiple distinct indications:

Peptic ulcer disease (adjunct): One of the oldest approved uses, dating to 1961. Oral tablets reduce gastric acid secretion and GI motility as an adjunct to ulcer treatment. Much less commonly used for this today with modern PPIs available.

Preoperative secretion reduction: Injectable glycopyrrolate is given before surgery to reduce saliva and respiratory secretions, block vagal cardiac reflexes, and counteract the effects of cholinesterase inhibitors used to reverse neuromuscular blockade.

Chronic severe drooling (sialorrhea) in children: Cuvposa is FDA-approved for children ages 3–16 with neurological conditions such as cerebral palsy that cause pathological drooling.

Primary axillary hyperhidrosis: Qbrexza topical cloths (approved June 2018) are the first FDA-approved topical anticholinergic for excessive underarm sweating in adults and children 9 years and older.

COPD maintenance: Inhaled glycopyrronium (Seebri Neohaler, Lonhala Magnair, Bevespi Aerosphere) as a long-acting muscarinic antagonist (LAMA) to relieve bronchospasm and improve lung function in COPD.

Is Glycopyrronium a Controlled Substance?

No. Glycopyrronium is not a controlled substance and has no DEA scheduling. It does not have abuse potential and is not regulated in the same way as opioids, benzodiazepines, or stimulants. Any licensed prescriber can prescribe it without special DEA registration for controlled substances, and there are no federal refill restrictions.

Dosage by Formulation

Oral tablets (peptic ulcer): Typically 1–2 mg two to three times daily; titrated upward based on response. Maximum dose determined by side effects.

Cuvposa (pediatric drooling): Starting dose 0.02 mg/kg three times daily (given 1 hour before or 2 hours after meals), increased by 0.02 mg/kg every 5–7 days as needed, up to 0.1 mg/kg TID. Maximum single dose: 1.5–3 mg (weight-based).

Qbrexza (topical): One cloth wiped over each underarm area once daily. Each cloth is single-use.

Seebri Neohaler / Lonhala Magnair (COPD): One capsule inhaled twice daily (Seebri) or one 25 mcg/mL vial via nebulizer twice daily (Lonhala Magnair).

Injectable (preoperative): 0.004 mg/kg IM 30–60 minutes before anesthesia; 0.1–0.2 mg IV for intraoperative vagal reflex management.

Key Contraindications

Glycopyrronium should NOT be used in patients with:

Narrow-angle (angle-closure) glaucoma

Myasthenia gravis

Severe ulcerative colitis or toxic megacolon

Urinary obstruction

Gastrointestinal obstruction (paralytic ileus)

Finding Your Glycopyrronium Prescription

Once you have a prescription, medfinder can call pharmacies near you to check which ones have your specific formulation in stock, saving you time on the search.

Want to understand how glycopyrronium actually works in the body? See our post on glycopyrronium mechanism of action.